Tango Therapeutics
Investors
Join Us
Contact
Science
Approach
Platform
Publications + Posters
Pipeline
Programs
PRMT5
CoREST
USP1
Clinical Trials
Leadership
Home
Science
▼
Approach
Platform
Publications + Posters
Pipeline
Programs
▼
PRMT5
CoREST
USP1
Clinical Trials
Leadership
Join Us
Investors
▼
Overview
News & Events
▼
News Releases
Events & Presentations
Governance
▼
Overview
Executive Leadership
Board of Directors
Committee Composition
Stock Information
▼
Stock Quote & Chart
Financials
▼
SEC Filings
Resources
▼
Investor FAQs
Email Alerts
Contact IR
Contact
Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor
Press Release
Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor
